Could GLP-1 Medications Help Treat Addiction?
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Early research suggests yes. A study of more than 600,000 U.S. veterans found that people taking GLP-1 medications had a 14% to 25% lower risk of developing substance use disorders across alcohol, opioids, cannabis, cocaine, and nicotine, according to findings published in The BMJ in March 2026 (WashU Medicine). The research is still early, but the signal is strong enough that major clinical trials are underway.
Who This Helps
This article is for anyone curious about what GLP-1 medications might do beyond weight loss and blood sugar management. If you are taking a GLP-1, considering one, or have noticed changes in cravings or habits since starting treatment, this research adds useful context. It is also relevant for anyone following the broader conversation about where these medications are headed.
GLP Winner tracks the latest developments in GLP-1 research and helps you compare providers offering different GLP-1 treatment programs.
What the WashU Study Found
Researchers at Washington University School of Medicine in St. Louis analyzed electronic health records from 606,434 U.S. veterans with type 2 diabetes. GLP-1 medications are a class of drugs that activate the GLP-1 receptor, a receptor involved in appetite, blood sugar regulation, and, as this research suggests, the brain's reward system. The participants were split into two groups: those without a pre-existing substance use disorder and those who already had one (WashU Medicine).
For people without a pre-existing substance use disorder, GLP-1 medication use was associated with a reduced risk of developing one:
- 18% lower risk for alcohol use disorder
- 14% lower risk for cannabis use disorder
- 20% lower risk for cocaine use disorder
- 20% lower risk for nicotine use disorder
- 25% lower risk for opioid use disorder
For people who already had a substance use disorder, those taking a GLP-1 had a 25% to 50% lower risk of emergency department visits, hospitalization, overdose, suicidal thoughts or attempts, and death.
What this means for you: This is observational data, meaning it shows an association, not proof that GLP-1 medications directly prevent or treat addiction. But the pattern held across every major substance category and in a very large population. That consistency is what makes researchers pay attention.
The JAMA Psychiatry Trial on Alcohol
A separate randomized clinical trial, published in JAMA Psychiatry in February 2025, tested semaglutide directly in adults with alcohol use disorder (JAMA Psychiatry). Semaglutide is the active ingredient in FDA-approved medications like Ozempic and Wegovy.
The trial found that over 9 weeks of treatment, semaglutide:
- Reduced the amount of alcohol consumed during a controlled laboratory self-administration test
- Significantly reduced weekly alcohol cravings compared to placebo
- Led to greater reductions in cigarettes per day among participants who also smoked
This was a small, short trial. The results are considered preliminary. But it was the first randomized controlled trial to directly test a GLP-1 medication specifically for alcohol use disorder, and the results were positive enough to lead to larger follow-up studies.
What this means for you: The clinical trial evidence is still in its early stages, but it supports what the larger observational studies have been showing. GLP-1 medications appear to affect cravings beyond just food.
Why GLP-1s Might Affect Addiction
The connection between GLP-1 medications and reduced substance use is not random. There is a biological explanation.
GLP-1 receptors are found throughout the brain, including in areas that regulate reward, motivation, and craving. These are the same brain circuits involved in addiction (Endocrine Society). When a GLP-1 medication activates these receptors, it appears to reduce the reward signal that drives repetitive behaviors, whether that behavior is overeating, drinking alcohol, or using other substances.
Anecdotal reports of people on GLP-1 medications noticing decreased interest in alcohol have circulated for years, and media coverage of this trend has been widespread (CNN). The clinical research is now catching up to explain why those reports align with biology.
GLP Winner follows the science behind GLP-1 medications and makes it easier to find providers who stay current with the latest research and treatment approaches.
What this means for you: GLP-1 medications may work on the same brain pathways that drive addiction. This does not mean they are approved or recommended for addiction treatment yet. But it helps explain why some people notice changes in cravings and habits beyond food after starting a GLP-1.
What Trials Are Running Right Now
Several major clinical trials are in progress or planned:
- Phase 3 semaglutide trial for alcohol use disorder. A larger trial is underway to evaluate the effectiveness, tolerability, and safety of semaglutide for alcohol use disorder at a larger scale (ClinicalTrials.gov)
- Novo Nordisk alcohol and liver disease trial. Novo Nordisk, the maker of Ozempic and Wegovy, has announced it will study how its medications affect alcohol consumption in people with alcohol-related liver disease (NPR via WSIU)
- Eli Lilly Brenipatide trial. Eli Lilly, the maker of Mounjaro and Zepbound, is testing an experimental drug called brenipatide on alcohol, tobacco, and opioid use disorders (NPR via WSIU)
These trials could take several years to produce results. If the findings are positive, GLP-1 medications could eventually receive FDA approval for addiction-related indications. That is a big "if," but the investment from major pharmaceutical companies shows they take the signal seriously.
What this means for you: No GLP-1 medication is currently FDA-approved for treating addiction. The trials are promising but early. If you or someone you know is dealing with substance use, talk to a healthcare provider about evidence-based treatment options that are available now.
What This Does Not Mean
A few things to be clear about.
GLP-1 medications are not a treatment for addiction today. They are FDA-approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy, Zepbound). Using them for addiction would be considered off-label, and the research does not yet support that use.
The WashU study was observational. Observational studies can show that two things are related but cannot prove one caused the other. People who take GLP-1 medications may differ from people who do not in ways the study could not fully account for.
The JAMA Psychiatry trial was small (just 48 participants) and short (9 weeks). Larger and longer trials are needed before any conclusions can be drawn about clinical use.
What this means for you: The research is exciting and worth watching. But it is early-stage science. Do not change any medication or treatment plan based on preliminary findings without talking to your provider.
Final Takeaway
GLP-1 medications were developed for blood sugar and weight. The possibility that they may also help with addiction came as a surprise to researchers and patients alike.
The early data is promising. The science behind it makes biological sense. Whether this leads to new FDA-approved uses will take time to determine. For now, it is a reason to pay attention and a reminder that we are still learning what these medications can do.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
GLP-1 use is altering grocery habits, dining menus, and product design in 2026 and beyond.
Learn how FDA-approved GLP-1 medications like Wegovy, Ozempic, Mounjaro, and Zepbound work—and what to know about compounded and next-gen options.
People are asking if GLP-1 medications could help with PCOS, fertility, or hormones. Here’s what science actually says — and what’s still unknown.
Curated by
